294 related articles for article (PubMed ID: 25041772)
21. Eltrombopag Effectiveness and Tolerability in Chronic Immune Thrombocytopenia: A Meta-Analysis.
Ahmed HAW; Masoud AT; Han J; Adel Sofy A; Saeed Ahmed A; Abdesattart AT; Drokow EK; Sun K
Clin Appl Thromb Hemost; 2021; 27():10760296211005555. PubMed ID: 33874785
[TBL] [Abstract][Full Text] [Related]
22. Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura.
Dmytrijuk A; Robie-Suh K; Rieves D; Pazdur R
Oncology (Williston Park); 2009 Nov; 23(13):1171-7. PubMed ID: 20043468
[TBL] [Abstract][Full Text] [Related]
23. Successful eltrombopag treatment of refractory idiopathic thrombocytopenic purpura associated with Crohn disease.
El Rassy E; Kourie HR; Nehme W; Georges S; Haddad E; Nasnas R; Nasr F
Clin Res Hepatol Gastroenterol; 2015 Apr; 39(2):e23-4. PubMed ID: 25497274
[No Abstract] [Full Text] [Related]
24. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.
Bussel JB; Cheng G; Saleh MN; Psaila B; Kovaleva L; Meddeb B; Kloczko J; Hassani H; Mayer B; Stone NL; Arning M; Provan D; Jenkins JM
N Engl J Med; 2007 Nov; 357(22):2237-47. PubMed ID: 18046028
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of eltrombopag in treatment-refractory primary immune thrombocytopenia: a retrospective study.
Eser A; Toptas T; Kara O; Sezgin A; Noyan-Atalay F; Yilmaz G; Ozgumus T; Pepedil-Tanrikulu F; Kaygusuz-Atagunduz I; Firatli-Tuglular T
Blood Coagul Fibrinolysis; 2016 Jan; 27(1):47-52. PubMed ID: 26258668
[TBL] [Abstract][Full Text] [Related]
26. A practical guide to the use of eltrombopag in children with chronic immune thrombocytopenia.
Grainger JD; Thind S
Pediatr Hematol Oncol; 2017 Mar; 34(2):73-89. PubMed ID: 28537785
[TBL] [Abstract][Full Text] [Related]
27. Eltrombopag for chronic immune thrombocytopenia.
Milosevic I; Slade E; Drysdale H;
Lancet; 2016 Jan; 387(10016):336. PubMed ID: 26842445
[No Abstract] [Full Text] [Related]
28. Eltrombopag in thrombocytopenia.
Zimmer J; Hentges F; Andrès E
N Engl J Med; 2008 Mar; 358(10):1072; author reply 1072-3. PubMed ID: 18326076
[No Abstract] [Full Text] [Related]
29. Eltrombopag for the treatment of idiopathic thrombocytopenic purpura.
Stasi R
Expert Rev Hematol; 2008 Dec; 1(2):145-52. PubMed ID: 21082919
[TBL] [Abstract][Full Text] [Related]
30. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
[TBL] [Abstract][Full Text] [Related]
31. Function of eltrombopag-induced platelets compared to platelets from control patients with immune thrombocytopenia.
Haselboeck J; Kaider A; Pabinger I; Panzer S
Thromb Haemost; 2013 Apr; 109(4):676-83. PubMed ID: 23389750
[TBL] [Abstract][Full Text] [Related]
32. Eltrombopag for chronic immune thrombocytopenia - Authors' reply.
Grainger JD;
Lancet; 2016 Jan; 387(10016):336-337. PubMed ID: 26842444
[No Abstract] [Full Text] [Related]
33. Eltrombopag in chronic idiopathic thrombocytopenic purpura.
Panzer S; Pabinger I
Lancet; 2009 Feb; 373(9664):607-8. PubMed ID: 19231614
[No Abstract] [Full Text] [Related]
34. Update on eltrombopag for ITP.
Bussel JB
Oncology (Williston Park); 2009 Nov; 23(13):1177-8. PubMed ID: 20043469
[No Abstract] [Full Text] [Related]
35. Successful discontinuation of eltrombopag in one child with refractory primary immune thrombocytopenia and literature review.
Wang X; Liu X; Wang L; Wang JY; Li A
Blood Coagul Fibrinolysis; 2019 Mar; 30(2):71-74. PubMed ID: 30720490
[TBL] [Abstract][Full Text] [Related]
36. Eltrombopag for the Treatment of Immune Thrombocytopenia: The Aegean Region of Turkey Experience.
Özdemirkıran F; Payzın B; Kiper HD; Kabukçu S; Akgün Çağlıyan G; Kahraman S; Sevindik ÖG; Ceylan C; Kadıköylü G; Şahin F; Keskin A; Arslan Ö; Özcan MA; Kabukçu G; Görgün G; Bolaman Z; Büyükkeçeci F; Bilgir O; Alacacıoğlu İ; Vural F; Tombuloğlu M; Gökgöz Z; Saydam G
Turk J Haematol; 2015 Dec; 32(4):323-8. PubMed ID: 25914025
[TBL] [Abstract][Full Text] [Related]
37. Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study.
Visco C; Rodeghiero F; Romano A; Valeri F; Merli M; Quaresimini G; Volpetti S; Santi RM; Carli G; Lucchini E; Passamonti F; Rambaldi A; Motta G; Borchiellini A; d'Amore ESG; Ruggeri M
Blood; 2019 Nov; 134(20):1708-1711. PubMed ID: 31570488
[TBL] [Abstract][Full Text] [Related]
38. Eltrombopag. Idiopathic thrombocytopenic purpura after treatment failure: romiplostim is a better option.
Prescrire Int; 2010 Feb; 19(105):15. PubMed ID: 20455333
[TBL] [Abstract][Full Text] [Related]
39. Two new drugs for chronic ITP.
Med Lett Drugs Ther; 2009 Feb; 51(1305):10-1. PubMed ID: 19197233
[TBL] [Abstract][Full Text] [Related]
40. [Neutrophil recovery by eltrombopag treatment in a patient with adult-onset autoimmune neutropenia and immune thrombocytopenia].
Tokunaga M; Yamada M; Kondo A; Mishima M; Yoshikawa S; Inoue S; Morita T; Tominaga N
Rinsho Ketsueki; 2018; 59(3):310-314. PubMed ID: 29618690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
